Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Francesco Merli
Institution:
Azienda Sanitaria Unità Locale di Reggio Emilia
Observed institution:
Azienda Sanitaria Unità Locale di Reggio Emilia
ORCID:
0000-0002-0979-7883
Observed ORCID:
0000-0002-0979-7883
OpenAlex ID:
A5113263400
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results
2024
·
Maurizio Martelli
, Luca Ceriani
, et al.
·
Journal of Clinical Oncology
·
44
Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group
2025
·
Carmen Martínez
, Irma Khvedelidze
, et al.
·
Bone Marrow Transplantation
·
7
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial
2024
·
Alessandro Pulsoni
, Simone Ferrero
, et al.
·
The Lancet Haematology
·
7
The importance of assessing the fitness of older patients with newly diagnosed diffuse large B‐cell lymphoma and classic Hodgkin lymphoma
2025
·
Vittorio Ruggero Zilioli
, Alessandra Tucci
, et al.
·
British Journal of Haematology
·
3
Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group
2024
·
Maria Carmen Martinez Munoz
, Irma Khvedelidze
, et al.
·
Blood
·
2
PDF
Show more works
View as search
Works count:
5
Citation count:
63
H-index:
3
I10-index:
1
Year
Topic
Type